An Assessment of the Bivalent Vaccine As a Second Booster for COVID-19

Overview

Journal Vaccines (Basel)

Date 2023 Jan 21

PMID 36679924

Authors

Sneh Lata Gupta

Rishi K Jaiswal

Affiliations

Soon will be listed here.

Abstract

In the USA, two monovalent COVID-19 mRNA vaccines are primarily used for vaccination [...].

Citing Articles

SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.

Angius F, Puxeddu S, Zaimi S, Canton S, Nematollahzadeh S, Pibiri A Vaccines (Basel). 2025; 13(1).

PMID: 39852796 PMC: 11769326. DOI: 10.3390/vaccines13010017.

Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination.

Walmsley S, Nabipoor M, Lovblom L, Ravindran R, Colwill K, Mcgeer A Vaccines (Basel). 2024; 12(1).

PMID: 38250849 PMC: 10820583. DOI: 10.3390/vaccines12010036.

Role of Immunoglobulin A in COVID-19 and Influenza Infections.

Tyagi R, Basu S, Dhar A, Gupta S, Gupta S, Jaiswal R Vaccines (Basel). 2023; 11(11).

PMID: 38005979 PMC: 10675305. DOI: 10.3390/vaccines11111647.

Children's SARS-CoV-2 Infection and Their Vaccination.

Gupta S, Tyagi R, Dhar A, Oswal N, Khandelwal A, Jaiswal R Vaccines (Basel). 2023; 11(2).

PMID: 36851295 PMC: 9962844. DOI: 10.3390/vaccines11020418.

References

Gupta S, Jaiswal R . Neutralizing antibody: a savior in the Covid-19 disease. Mol Biol Rep. 2022; 49(3):2465-2474. PMC: 8731133. DOI: 10.1007/s11033-021-07020-6. View

Scheaffer S, Lee D, Whitener B, Ying B, Wu K, Liang C . Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nat Med. 2022; 29(1):247-257. PMC: 11752949. DOI: 10.1038/s41591-022-02092-8. View

Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J . Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med. 2022; 28(11):2388-2397. PMC: 9671805. DOI: 10.1038/s41591-022-02031-7. View

Rosenblum H, Wallace M, Godfrey M, Roper L, Hall E, Fleming-Dutra K . Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(45):1436-1441. PMC: 9707353. DOI: 10.15585/mmwr.mm7145a2. View

Chalkias S, Harper C, Vrbicky K, Walsh S, Essink B, Brosz A . A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med. 2022; 387(14):1279-1291. PMC: 9511634. DOI: 10.1056/NEJMoa2208343. View

Gupta S, Mantus G, Manning K, Ellis M, Patel M, Ciric C . Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults. J Virol. 2022; 96(17):e0058222. PMC: 9472620. DOI: 10.1128/jvi.00582-22. View

Gupta S, Jaiswal R . Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage. Mol Biol Rep. 2022; 49(10):10137-10140. PMC: 9123622. DOI: 10.1007/s11033-022-07493-z. View

Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M . Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine. N Engl J Med. 2023; 388(9):854-857. PMC: 9891359. DOI: 10.1056/NEJMc2214916. View

Davis-Gardner M, Lai L, Wali B, Samaha H, Solis D, Lee M . Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; 388(2):183-185. PMC: 9812288. DOI: 10.1056/NEJMc2214293. View

10.

Collier A, Miller J, Hachmann N, McMahan K, Liu J, A Bondzie E . Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters. N Engl J Med. 2023; 388(6):565-567. PMC: 9847505. DOI: 10.1056/NEJMc2213948. View

11.

Fang Z, Monteiro V, Hahn A, Grubaugh N, Lucas C, Chen S . Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5. Cell Discov. 2022; 8(1):108. PMC: 9552143. DOI: 10.1038/s41421-022-00473-4. View

12.

Link-Gelles R, Levy M, Natarajan K, Reese S, Naleway A, Grannis S . Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023; 6(3):e232598. PMC: 10018321. DOI: 10.1001/jamanetworkopen.2023.2598. View

13.

Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L . Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. N Engl J Med. 2023; 388(6):567-569. PMC: 9847504. DOI: 10.1056/NEJMc2213907. View

14.

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View